NCT04453189

A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants

A Phase 1, Open-label, Randomized, 2-Way Crossover Study to Assess the Effects of Acid-Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of JNJ-64417184 in Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary purpose of this study is to evaluate the effect of multiple-dose administration of lansoprazole on the single-dose pharmacokinetics (PK) of JNJ-64417184 in healthy adult participants; and to evaluate the effect of time-separated, multiple-dose administration of famotidine on the single-dose PK of JNJ-64417184 in healthy adult participants (optional).

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	JNJ-64417184	Participants will receive single dose of JNJ-64417184 in fed condition on Day 1 in assigned treatment sequence.
DRUG	Lansoprazole	Participants will receive lansoprazole once daily in fasted condition on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5 in assigned treatment sequence.
DRUG	Famotidine	Participant will receive famotidine in fasted condition on Day 1 in assigned treatment sequence.

Timeline

• Start date: 2020-07-20
• Primary completion: 2020-09-14
• Completion: 2020-09-14
• First posted: 2020-07-01
• Last updated: 2025-02-03

Locations

1 site across 1 country: Netherlands